Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE).
Updated clinical guidelines provide clear monitoring and intervention thresholds for preventing and managing heart damage from leukemia drugs in children, supporting long-term survivorship.
This SFCE practice guideline provides updated recommendations for managing anthracycline-related cardiotoxicity in children and adolescents with acute leukemia, addressing a critical long-term survivorship concern. The guideline covers monitoring frequency, imaging criteria, and cardioprotective intervention thresholds for pediatric hematology-oncology practice.
What the study was
- Study design
- Clinical practice guideline
- Population
- Children and adolescents with acute leukemia receiving anthracycline-based therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Bulletin du Cancer
Why it surfaced
National practice guideline from SFCE for cardiotoxicity management in pediatric acute leukemia — clinically actionable within pediatric hematology-oncology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.